Business Context and Reporting Period
This Form 8-K was filed by Health Sciences Acquisitions Corporation 2 (HSAC2) on July 22, 2022. HSAC2 is a Cayman Islands exempted company and an emerging growth company. The filing addresses an upcoming extraordinary general meeting scheduled for July 26, 2022, to vote on extending the deadline to consummate a business combination with Orchestra BioMed, Inc.
Key Financial Metrics and Liquidity
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Key liquidity-related figures disclosed include:
- Redemption Requests: As of July 22, 2022, shareholders requested redemption for 9,237,883 ordinary shares.
- Share Purchase Transaction: RTW Funds (an affiliate of the sponsor) purchased 1,000,000 ordinary shares at $10.01 per share from an accredited investor.
- Trust Account: The purchase was structured to ensure funds that would have been paid for redemptions remain in the trust account to support the proposed business combination.
Material Changes and Events
The primary material event is the proposed amendment to the Company's charter to extend the liquidation deadline. If approved, the termination date will move from August 6, 2022, to November 6, 2022. Additionally, the amendment would allow the Company to extend the deadline monthly for up to three additional months (until February 6, 2023) without further shareholder votes. The filing also discloses a privately negotiated share purchase by the sponsor's affiliate to bolster the likelihood of the business combination closing.
Guidance, Outlook, and Risks
Outlook: Management is seeking shareholder approval to extend the timeline to complete the merger with Orchestra BioMed, Inc. The recent share purchase by the sponsor's affiliate is intended to prevent share redemptions and maintain trust account liquidity for the transaction.
Risks: The business combination is contingent upon shareholder approval of the extension proposal. If the extension is not approved, the Company must liquidate and dissolve by August 6, 2022. The filing does not provide specific risk factors beyond the standard implications of a SPAC extension vote.
Investor Verification Checklist
- Verify the outcome of the shareholder vote on the Extension Proposal scheduled for July 26, 2022.
- Confirm the final number of shares redeemed versus the 9,237,883 requested as of July 22, 2022.
- Review the definitive proxy statement dated July 1, 2022, for full details on the proposed business combination with Orchestra BioMed, Inc.
- Monitor subsequent filings for updates on the closing of the business combination or the Company's liquidation status if the extension fails.